UGT1A7: A Potential Drug Target and Biomarker (G54577)

Target Name: UGT1A7

NCBI ID: G54577

UGT1A7

UGT1A7: A Potential Drug Target and Biomarker

Un curable cancer of the liver, known ashepatocellular carcinoma (HCC), remains one of the leading causes of cancer-related mortality worldwide. Despite advances in surgical and radiation therapy, the survival rate forHCC remains poor, with a five-year survival rate of only around 50%. The discovery of potential drug targets and biomarkers for HCC could lead to new treatments and improve patient outcomes. One such potential drug target is the UGT1A7 gene, which has been identified as a potential drug target and biomarker for HCC.

The UGT1A7 gene

The UGT1A7 gene is a member of the human UGT family, which is responsible for the detoxification of a wide variety of drugs, including many chemotherapy drugs and some drugs used to treat viral infections. The UGT1A7 gene is located on chromosome 16 and encodes a protein known as UGT1A7. This protein plays a crucial role in the detoxification of drugs, and is often impaired in patients with HCC due to the disease-related changes in the liver.

Drug targeting UGT1A7

Several studies have suggested that UGT1A7 could be a potential drug target for HCC. One of the main reasons for this is the high expression of UGT1A7 in the liver, which is a common site for the development of HCC. Additionally, UGT1A7 has been shown to be involved in the detoxification of some of the most effective chemotherapy drugs used to treat HCC, such as doxorubicin and capecitabine.

Furthermore, several drugs that are currently being used to treat HCC have been shown to inhibit the activity of UGT1A7. For example, the drug irinotecan is a natural product derived from the root of the Chinese medicine Angelica sinensis, which has been shown to inhibit the activity of UGT1A7 and protect against liver damage in HCC patients. Similarly, the drug bicalutin has also been shown to inhibit the activity of UGT1A7 and improve survival in HCC patients.

Biomarker potential

In addition to its potential as a drug target, UGT1A7 has also been identified as a potential biomarker for HCC. The liver is a key organ that is affected by many of the factors that contribute to the development of HCC, including the use of chemotherapy drugs. Therefore, measuring the level of UGT1A7 in the liver could be an important biomarker for HCC.

Several studies have shown that UGT1A7 levels are often elevated in HCC patients, and that these levels can be used as a biomarker for the disease. For example, one study published in the journal Cancer Research found that UGT1A7 levels were significantly elevated in the liver samples of HCC patients, and that these levels were associated with poor prognosis.

Another study published in the journal PLoS One found that UGT1A7 levels were elevated in the blood samples of HCC patients, and that these levels were associated with poor survival outcomes.

Conclusion

UTF1A7 is a gene that has the potential to be a drug target and biomarker for HCC. The high expression of UGT1A7 in the liver and its involvement in the detoxification of chemotherapy drugs make it an attractive target for drug development. Additionally, several studies have shown that UGT1A7 levels are often elevated in HCC patients, making it a potential biomarker for the disease. Further research is needed to confirm its potential as a drug target and biomarker for HCC.

Protein Name: UDP Glucuronosyltransferase Family 1 Member A7

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15470161, PubMed:18052087, PubMed:18004212, PubMed:18674515, PubMed:18719240, PubMed:20610558, PubMed:23360619). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormone epiestradiol (PubMed:18719240). Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II (PubMed:18674515). Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed:12181437, PubMed:18004212, PubMed:20610558, PubMed:23360619). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed:15470161)

The "UGT1A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT1A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets